Usefulness of propafenone for supraventricular arrhythmias in infants and children

Dressler, 1985, Die Behandlung von Herzrhythmusstörungen mit Propafenon bei Säuglingen und Kindern, Monatsschr Kinderheilk, 133, 154 Lucet, 1987, Efficacite antiarythmique de la propafenone chez l'enfant, Arch Mal Coeur, 9, 1385 Musto, 1988, Electrophysiological effects and clinical efficacy of propafenone in children with recurrent paroxysmal supraventricular tachycardia, Circulation, 78, 863, 10.1161/01.CIR.78.4.863 Weber, 1983, Erfahrungen mit Propafenon bei der Behandlung von Rhythmusstorungen im Kindesalter, 185 Reimer, 1991, Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias, Am J Cardiol, 68, 741, 10.1016/0002-9149(91)90646-3 Garson, 1987, Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia, Am J Cardiol, 59, 1422, 10.1016/0002-9149(87)90935-0 Guccione, 1991, Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up, Am Heart J, 122, 1022, 10.1016/0002-8703(91)90467-V Siddoway, 1987, Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences, Circulation, 75, 785, 10.1161/01.CIR.75.4.785 Price-Evans, 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population, J Med Genet, 17, 102, 10.1136/jmg.17.2.102 Nakamura, 1985, Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin Pharmacol Ther, 38, 402, 10.1038/clpt.1985.194 Steiner, 1985, A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin, Clin Pharmacol Ther, 38, 394, 10.1038/clpt.1985.193 Lee, 1990, The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone, N Engl J Med, 322, 1764, 10.1056/NEJM199006213222502 Kulpmann, 1986, Gas Chromatographic determination of propafenone by use of a “530 μm” capillary column, J Clin Chem Biochem, 24, 803 McHugh, 1987, Propafenone ingestion, Ann Emerg Med, 16, 437, 10.1016/S0196-0644(87)80367-0 Konz, 1984, Cholestase nach antiarrhythmischer Therapie mit Propafenone, Dtsch Med Wochenschr, 109, 1525, 10.1055/s-2008-1069406 Schuff-Werner, 1980, Cholestatische Hepatitis nach antiarrhythmischer Therapie mit Propafenon, Dtsch Med Wochenschr, 105, 137 Schuff-Werner, 1981, Propafenon-induzierte Cholestatische Hepatitis, Z Gastroenterol, 19, 673 Scanu, 1991, Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate, PACE, 14, 783, 10.1111/j.1540-8159.1991.tb04107.x Buss, 1985, Malignant ventricular tachyarrhythmias in association with propafenone treatment, Eur Heart J, 6, 424, 10.1093/oxfordjournals.eurheartj.a061881 Fish, 1991, Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide, J Am Coll Cardiol, 18, 356, 10.1016/0735-1097(91)90586-X